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Background. Whether or not the familial form of papillary thyroid carcinoma is more aggressive than the sporadic form of the
disease remains controversial. Methods. To explore this question and whether or not increased aggressiveness is more apparent in
families with multiple aﬀected members, we performed a chi square by trend analysis on our patients clinical and pathologic data
comparing: ﬁrst degree families with three or more aﬀected members versus ﬁrst degree families with two aﬀected members versus
sporadic cases of papillary thyroid carcinoma. Results. No statistically signiﬁcant trends were seen for any presenting surgical
pathology parameter, age at presentation, length of follow-up or gender distribution. The familial groups exhibited signiﬁcant
trends for higher rates of reoperation (P = 0.05) and/or requiring additional radioactive iodine therapy (P = 0.03), distant
metastases (P = 0.003) and deaths (P = 0.01). These aggressive features were most apparent in certain families with three or
more aﬀected members. Conclusions. Using the chi square by trend analysis, a signiﬁcant trend was seen for the familial form of
papillary thyroid cancer to possess more aggressive features than the sporadic disease. Prompt recognition of the familial nature of
the disease may provide earlier diagnosis and treatment in similarly aﬀected family members.
1.Introduction
Early reports of well-diﬀerentiated nonmedullary thyroid
carcinoma clustering in families [1–7], and studies utilizing
population and hospital data bases [8–13] demonstrating
that such cases occurred in families more often than could
be explained by chance have led to the general acceptance of
the existence of a familial form of the disease. Most reported
familial cases are papillary carcinoma, including familial
papillary thyroid microcarcinoma [14]. A hereditary basis
for this familial nonmedullary thyroid cancer is postulated,
but no speciﬁc genetic defect has been established as yet
[15–17], and the suggestion has been made that the disease
may result from a heterogeneous form of inheritance or
the interaction of susceptibility genes with unidentiﬁed
environmental factors [17–19].
Aspects of the natural history of familial papillary
thyroid carcinoma (FPTC) remain unclear, and speciﬁcally
controversial is whether or not the familial form of the
disease is more aggressive than the sporadic form. In certain
reports, the familial form of the disease was associated with
an earlier age at diagnosis [3, 7], a higher than usual ratio of
male to female cases [14, 20], a greater incidence of spread
outside the thyroid gland, [3, 14, 20, 21]a n dag r e a t e rr a t eo f
persistence/recurrence [7, 14, 20–23] .H o w e v e r ,an u m b e ro f
other studies did not conﬁrm the presence of these measures
of aggressiveness, including a recent retrospective study [24],
and, in a review of published studies, Loh [25] did not
ﬁnd conclusive evidence for increased aggressiveness in the
familial form of the disease. Charkes [26] has pointed out
thatmostreportsconsistpredominantlyoffamilieswithonly
two aﬀected members, and in his analysis a high percentage2 Journal of Oncology
(62–69%) of patients in two member families may suﬀer
fromthesporadicratherthanthefamilialformofthedisease.
Hence, a number of reports may have included the data from
a signiﬁcant number of sporadic cases in their analysis of
the characteristics of familial cases. In contrast, kindred’s
with three or more aﬀected members overwhelmingly (96%)
represent the familial form of the disease [26], leading
Charkes to suggest that these kindred’s be used for clinical
and genetic investigations. Further, as FPTC may be a
heterogeneous entity, there may be signiﬁcant diﬀerences in
thedegreeofaggressivenessbetweendiﬀerentfamilieswithin
any given report of cases, rendering comparisons in series
with small numbers of families diﬃcult.
In this communication, we describe a retrospective anal-
ysis of our experience with sporadic versus FPTC cases seen
at the University of Western Ontario. Given Charkes’ analysis
and recommendations [26], we chose a statistical approach
designed to determine the presence or absence of a trend
for the occurrence of more aggressive disease in families
with three or more aﬀected members by comparing the
clinical and pathology ﬁndings of sporadic cases versus ﬁrst
degree families with two aﬀectedmembers versus ﬁrst degree
familieswiththree ormore aﬀected members. This approach
was chosen to address the issue of mistaking sporadic
cases for familial cases in two member families, and to
address the possibility that abnormal genes causing a higher
prevalence of disease may also result in more aggressive
disease. We further explored the possible presence of disease
heterogeneity occurring between FPTC families (i.e., the
possible presence of an aggressive genotype clustering in
certain families while other families contain members with
a genotype resulting in more indolent disease).
2.MaterialsandMethods
Patients attending our clinics at the University of Western
Ontario with an established diagnosis of nonmedullary
thyroid cancer were questioned regarding the presence or
absence of similarly aﬀected family members. We attempted
to conﬁrm the diagnosis of identiﬁed additional aﬀected
members by obtaining their medical and pathology records
and when possible reviewed these family members in our
clinic. The surgical pathology, therapeutic, and followup
data on all cases were entered into an access database
organizedintofourcategories:(1)sporadiccases,(2)familial
cases with aﬀected second degree or higher relatives, (3)
familial cases with ﬁrst degree relatives in families containing
only two aﬀected members, and (4) familial cases with
ﬁrst degree relatives in families containing three or more
similarly aﬀected individuals. For all cases, we entered into
thedatabasedetailsoftheclinicalcourse(includingevidence
of recurrence/persistence of disease such as reoperation,
requirement for additional radioactive iodine therapy, etc.)
and surgical pathology results including histological tumour
type; tumour number, size, and site; the presence or absence
of(a)tumourpenetrationofthyroidcapsuleand/orpresence
inperithyroidaltissue,(b)vascularorlymphaticinvasion,(c)
diﬀuse lymphocytic inﬁltration, (d) multifocal disease, (e)
bilateraldisease,(f)cervicalnodalmetastases,and(g)distant
metastases. The presence of distant metastatic disease was
established by surgical removal or biopsy of thyroid cancer-
ous tissue or by persistent radio-iodine uptake in abnormal
sites (e.g., lung, bone, CNS, etc.) with no other known cause.
Reoperationwasdeﬁnedasanysurgerycarriedouttoremove
proven recurrent/persistent thyroid cancer after the initial
surgical therapy of a total thyroidectomy (one or two stage
procedure). Deaths were attributed to thyroid cancer only if
other causes of death could be ruled out. Radioactive iodine
therapy was administered in accordance with the American
Thyroid Association guidelines.
Within the ascertainment time of case acquisition, the
data base contained 698 conﬁrmed cases of nonmedullary
well-diﬀerentiated thyroid cancer. Of these cases, 664 were
papillary thyroid cancer (Table 1), and all cases unequiv-
ocally established as occurring in a familial setting were
classiﬁed pathologically as papillary thyroid cancer. Hence
the term familial papillary thyroid cancer (FPTC) is used in
this paper. None of the established FPTC families had any
evidence of additional tumours or clinical features to suggest
thepresenceofafamilialsyndrome[18,27,28]charact erized
by a predominance of nonthyroidal tumours, for example,
familial adenomatous polyposis, PTEN-hamartoma syn-
drome, Carney complex, and so forth. This study was
approved by the Ethics Review Board for Human Research
at the University of Western Ontario.
Sixty patients presenting in our clinic gave a history of
ﬁrst degree relatives being similarly aﬀected with PTC; by
history, 22 families contained 3 or more similarly aﬀected
ﬁrstdegreerelativeswithPTC(datawasadequateforanalysis
on 52 patients), and 38 families had only 2 aﬀected members
(data was adequate for analysis on 55 of these patients).
An additional 33 families with similarly aﬀected second
degree or higher relatives were identiﬁed (data was adequate
for analysis on 36 of these patients). These patients form
a data set derived from families classiﬁed by historical
evidence alone without the necessity of having obtained
conﬁrmatory pathology on all family members. This data
set (the history-deﬁned data set) was analyzed as described
below, comparing four groups: ﬁrst degree relative families
with three or more aﬀected members, versus ﬁrst degree
relative families with two aﬀected members, versus second
degree or greater relative families with aﬀected members,
versus 521 concurrent sporadic cases. This history-deﬁned
data set was analyzed as described below, and the results are
presented in Table 5.
On review of the pathology data obtained on additional
identiﬁed family members, we were able to conﬁrm (in
all members) a pathology proven status of 14 ﬁrst degree
relative families with 3 or more aﬀected members (41
members of this group had adequate data for analysis) and
30 ﬁrst degree families with only 2 aﬀected members (50
members of this group had adequate data for analysis). We
performedanidenticalstatisticalanalysisonthisdataset(the
pathology-deﬁned data set) comparing the presenting and
clinical followup data on three groups: ﬁrst degree families
containing 3 or more aﬀected members versus ﬁrst degree
family members containing 2 aﬀected members versus 521
PTC patients with sporadic disease seen concurrently. TheJournal of Oncology 3
Table 1: (a) Nonmedullary well-diﬀerentiated thyroid cancers. (b)




Follicular carcinoma 19 2.7
Hurthle cell carcinoma 14 2.0
Clear cell carcinoma 1 0.1
Papillary thyroid carcinoma 664 95.1
Total 698
(b)
Subtype Number of cases
Classical/follicular 626
Foci of oxyphil cell variant 15
Foci of tall cell variant 13
F o c io fs o l i dc e l lg r o w t hp a t t e r n 1 0
Total 664
results of this analysis on the pathology-deﬁned data set are
presented in detail in the text and in Tables 2–4.
To assess the validity of classifying families based on
historicalevidencealonewithoutrequiringpathologicalcon-
ﬁrmation of the presence of PTC in all additional identiﬁed
members, we subjected the data sets obtained from both the
history-deﬁned families and the pathology-deﬁned families
to identical statistical analyses. The results from the analyses
of the two data sets yielded identical statistical results. For
the sake of brevity, only the results of the pathology-deﬁned
data set are given in detail in the text and in Tables 2, 3,a n d
4. Table 5 displays the most relevant data from the history-
deﬁned data set together with a comparison of the statistical
results derived from the analysis of both data sets.
For statistical analysis, mean ages were contrasted using
analysis of variance, and distribution of gender in the groups
was compared using the chi-square test for contingency
tables. The method of statistical analysis was chi square by
trend for the frequency of the presenting surgical pathology
parameters, metastases, and for the followup data including
subsequent required treatments relative to the extent of
familial incidence of papillary thyroid cancer; the Cochran-
Armitage test was used for evaluation. Due to small counts
forsomeevents,the“exact”versionoftheCochran-Armitage
test was utilized. To examine for heterogeneity of disease
between individual families in the ﬁrst degree relative
categories, the log linear model with Poisson count was used
to model disease deaths and distant metastases by family
memberships. P values for the exact test were calculated
using StatXact software (Cytel Software Corporation, Cam-
bridge, Mass., USA). Statistical signiﬁcance was accepted for
P-values ≤0.05.
3. Results
Tables 1(a) and 1(b) display the diagnostic details for all 698
patients with nonmedullary thyroid cancer in the database.
The overwhelming majority of cases, 664 patients (95.1%),
were diagnosed with papillary carcinoma, 13 cases contained
areas of the tall cell variant, 15 cases contained areas of
the Oxyphil cell variant of PTC, and 10 had areas of solid
type growth patterns. The non-PTC cases were classiﬁed as
19 follicular carcinomas, 14 Hurthle cell carcinomas (11 of
which were classiﬁed as minimally invasive), and one clear
cell carcinoma. There were four sets of apparently identical
twins. Three of the four sets had concordant diagnoses of
PTC (all made within one year of each other); the fourth set
has one twin with proven PTC, the other twin is currently
under ongoing investigation for nodular disease, and a
furthersiblinghastreatedPTC.Threeofthefoursetsoftwins
occur in families with additional members with PTC, the
fourthsetoccursinafamilywithprominentnodulardisease.
Ten of the 13 cases with foci of the tall cell variant PTC
occurredinthenonfamilialcases,oneinaﬁrstdegreerelative
(3 or greater) family member who did not demonstrate any
aggressive features at surgery nor on followup, and in two
members of the second degree or greater relative families
(both of which had distant metastases). There were 10 cases
of PTC with foci of solid type growth pattern, all of which
occurred in sporadic PTC cases. None of the familial cases
had prior head and neck radiation.
The demographics of the nonfamilial and the PTC
familial cases are shown in Table 2. There was no statistically
signiﬁcant diﬀerence in the age at diagnosis between the
nonfamilial and familial cases, and a predominance of
females to males was seen in all groups with no statistically
signiﬁcantdiﬀerencesinsexdistributionbetweenthegroups.
Similarly, no signiﬁcant diﬀerence between the familial and
nonfamilial cases was found in the percentage of patients
aged 45 or older at diagnosis (Table 2), nor was there any
signiﬁcant diﬀerence in the average length of followup.
There were no statistically signiﬁcant diﬀerences seen for
any of the surgical pathology parameters analyzed (Table 3)
including tumour size greater than 3cm, presence of tumour
in perithyroidal tissue/penetration of thyroid capsule, multi-
focal or bilateral disease, vascular or lymphatic invasion, and
lymphocytic inﬁltration. Similarly, there was no statistically
signiﬁcant diﬀerence in the presence of cervical nodal
metastases between the groups (Table 4). In contrast, the
presence of distant metastases was statistically signiﬁcantly
higher in the familial cases than in the sporadic cases (P =
0.003), the distant metastases being seen particularly in
families with three or more aﬀected members (Table 4). The
familial group had statistically signiﬁcant increased rates of
recurrent/persistent disease as judged by the requirement for
reoperation (P = 0.05), the requirement of additional radio-
active iodine therapy administered at least two years after the
initial therapy (P = 0.03), or a combination of these two
therapeutic modalities (P = 0.03). Although the number
of deaths due to thyroid cancer was small over the time
period of case ascertainment, with the statistical approach
used there was a statistically signiﬁcant trend for greater
mortality (P = 0.01) in the familial groups. The two deaths
in the ﬁrst degree relative families with 3 or more aﬀected
members group occurred in one family which had multiple
members aﬀected by the disease (a third member is thought4 Journal of Oncology
Table 2: Demographics of nonfamilial and familial cases.
Nonfamilial 1st Degree, 2
members
1st Degree, 3 or
more members P value
No. of patients 521 50 41
Mean age at diagnosis (yrs ± SEM) 44.3 ±0.65 40.12 ± 1.9 43.2 ±1.90 . 1 4
No. of patients with diagnosis at age >45 223 (42.8%) 17 (34.0%) 17 (41.5%) 0.55
No. of females 414 (79.5%) 42 (84.0%) 30 (73.2%) 0.65
Mean length of followup (yrs ± SEM) 4.22 ±0.18 4.83 ±0.69 5.37 ±0.83 0.18
Table 3: Surgical pathology results of nonfamilial and familial cases.
Nonfamilial 1st Degree,
2m e m b e r s
1st Degree,
3o rm o r em e m b e r s P value
No. of patients 521 50 41
Tumour > 3.0cm 126 (24.2%) 12 (24.0%) 8 (19.5%) 0.61
Tumour in perithyroidal tissue/thyroid
capsule penetration 87 (16.7%) 8 (16.0%) 11 (26.8%) 0.17
Multifocal disease 272 (52.2%) 31 (62.0%) 23 (56.1%) 0.34
Bilateral disease 170 (32.6%) 20 (40.0%) 16 (39.0) 0.25
Vascular/lymphatic invasion 58 (11.1%) 7 (14.0) 5 (12.2%) 0.73
Lymphocytic inﬁltration 215 (41.3%) 19 (38.0%) 16 (39.0%) 0.71
Table 4: Metastases and clinical course.
Nonfamilial 1st Degree, 2
members
1st Degree, 3 or
more members P value
No. of patients 521 50 41
Cervical nodes positive 98 (18.8%) 12 (24.0%) 10 (24.4%) 0.27
Distant metastases 16 (3.1%) 2 (4.0%) 6 (14.6%) 0.003
Additional surgery 27 (5.2%) 2 (4.0%) 6 (14.6%) 0.05
Additional RAI >2yrs after initial treatment 13 (2.5%) 4 (8.0%) 3 (7.3%) 0.03
Reoperation or additional RAI, 2yrs after
initial treatment 34 (6.5%) 6 (12.0%) 6 (14.6%) 0.03
Deaths due to disease 2 (0.4%) 1 (2.0%) 2 (4.9%) 0.01















No. of patients 521 36 55 52
Tumour in perithyroidal tissue/thyroid
Capsule penetration 87 (16.7%) 8 (22.2%) 9 (16.4%) 15 (28.8%) 0.08 0.17
Multifocal 272 (52.2%) 22 (61.1%) 36 (65.5%) 31 (59.6%) 0.06 0.34
Vascular/lymphatic invasion 58 (11.1%) 6 (16.7%) 8 (14.5%) 6 (11.5%) 0.56 0.73
Cervical nodes positive 98 (18.8%) 8 (22.2%) 15 (27.3%) 13 (25.0%) 0.10 0.27
Distant metastases 16 (3.1%) 2 (5.6%) 3 (5.5%) 7 (13.5%) 0.002 0.003
Deaths 2 (0.4%) 1 (2.1%) 1 (1.8%) 2 (3.1%) 0.02 0.01
Reoperation 27 (5.2%) 2 (5.6%) 2 (3.6%) 8 (15.4%) 0.03 0.05
RAI, Additional treatment, 2 years after initial
treatment 13 (2.5%) 2 (5.6%) 4 (7.3%) 4 (7.7%) 0.01 0.03Journal of Oncology 5
to have died of the disease but the cause of death could
not be established with certainty); both patients presented
late in the course of the disease (as was the case for the
deaths occurring in both the familial and sporadic groups).
There were 24 cases with distant metastases (Table 4), 16
in the sporadic disease group and 8 in the familial group.
The presence of distant disease was discovered close to or
at the time of diagnosis of thyroid cancer in almost all
of the patients (a) in the sporadic disease group, 12 cases
had the distant spread discovered at the time of diagnosis
of thyroid cancer, 3 cases within the ﬁrst year, and in one
case the precise time elapsed was uncertain, (b) in the 6
familial cases found in the three or more member families
group, 3 had the distant spread discovered at the time of
diagnosis of thyroid cancer, 2 patients within one year, and
within two years in 1 patient, and (c) in the families with
two aﬀected members only, one patient was diagnosed with
distant metastases within one year and one case eighteen
years after the original diagnosis of thyroid cancer. An
additionalanalysis,performedtoexploreforheterogeneityin
our ﬁrst degree families, did not ﬁnd any statistical evidence
for the presence of heterogeneity for either deaths (P = 0.25)
or distant metastases (P = 0.54). However, it is noted that
the number of events analyzed was small; perhaps a greater
numberofeventswouldbenecessarytoperformanadequate
analysis.
Table 5 presents the most relevant data from the history-
deﬁned family groups data set and compares the statistical
results obtained in this group to the results obtained on the
data set of the pathology-deﬁned family groups. In agree-
ment with the analysis of the pathology-deﬁned family data
set, there were no statistically signiﬁcant trend diﬀerences
seen in any of the demographic data (age at diagnosis,
sex distribution, mean followup time, and percentage of
patients diagnosed after the age of 45 years). There were no
signiﬁcant diﬀerences seen in any of the surgical pathology
data although the history-deﬁned data set analysis results
approached signiﬁcance in certain parameters: tumour in
perithyroidal tissue/thyroid capsule penetration (P = 0.08),
multifocal disease (P = 0.06), and bilateral disease (0.07).
Statistically signiﬁcant trends also were seen for distant
metastases (0.002), deaths (0.02), reoperation (0.03), and
requirement for additional RAI (P = 0.01). Hence, the
statistical results are consistent using either approach to
deﬁning the family groups.
4. Discussion
Despite the presence of a number of reports on the subject,
it remains controversial as to whether the familial form of
PTC is more aggressive than the sporadic form of the disease.
Possible reasons for this uncertainly include the potential
for PTC to reappear long after the initial therapy, the
relatively infrequent occurrence of the familial form of the
disease (most studies report an incidence of approximately
5% of PTC cases, but one recent prospective study (32)
reports an incidence of 9.4% of PTC being familial), the
unrecognized inclusion of sporadic cases in the analysis of
familial disease characteristics and the possibility of FPTC
being a heterogeneous disease resulting in varying degrees
of aggressiveness occurring between diﬀerent families. In
this study, we used a diﬀerent statistical approach, the Chi
square for trend analysis, comparing the characteristics of
sporadic cases versus cases in ﬁrst degree relative families
with only 2 aﬀected members versus cases in ﬁrst degree
families with 3 or more aﬀected members. With this method
of data analysis, our study found a statistically signiﬁcant
trend for the familial disease to exhibit more aggressiveness
in certain disease characteristics and to require further
intervention after the initial therapy. Most studies have
deﬁned their family groups using historical data derived
from presenting patients. We compared the data derived
fromusingahistoricalapproach(historydeﬁned)todeﬁning
the family groups (i.e., the number of aﬀected patients in
a family) to that derived from family groups deﬁned by
requiring pathological conﬁrmation of allincluded members
(pathology deﬁned) by subjecting both data sets to identical
analyses. This comparison yielded identical statistical results;
it appears that with an important disease entity such as PTC,
families possess a good understanding of the family medical
history.
The data for this study is derived from patients residing
in an ethnically diverse population in which, similar to
other regions, the incidence of PTC is clearly rising [29].
PTC accounted for 95.1% of our cases of well-diﬀerentiated
thyroidcancerandthefemale-to-maleratioofcasesissimilar
to that reported in other areas. We did not see any signiﬁcant
diﬀerence in the proportion of female-to-male cases between
the sporadic and familial cases in agreement with some
reports [7, 24, 30] but in contrast to others [14, 20]w h i c h
found a higher than expected proportion of males in the
familial cases. Similar to other reports [6, 20], we did not
see a signiﬁcant trend towards an earlier age at diagnosis of
FPTC, but other studies do report an earlier age at diagnosis
of the familial disease [3, 7, 30]. We did not ﬁnd statistically
signiﬁcant diﬀerences between the nonfamilial and familial
cases in any of the surgical pathology parameters. It had
been reported that the familial form of the disease has a
greater incidence of cervical nodal metastases [3, 20–22], but
we did not ﬁnd any such increase. The multifocal nature
of the disease was a very common ﬁnding in all of our
cases (present in 52.2 to 65.5%), as was the presence of
bilateral disease in all groups, but there were no signiﬁcant
diﬀerences seen between the familial and sporadic cases; a
higherincidenceofmultifocalityhasbeenreportedincertain
series [6, 7, 14, 20, 27]. We did not see a trend to a larger size
of the primary tumour in the familial cases nor, somewhat
surprisingly, any diﬀerence in the ﬁnding of vascular or
lymphatic invasion by tumour. Although there was a greater
incidence of tumour presence in perithyroidal tissues in the
three or more member families, this was not statistically
signiﬁcantly diﬀerent.
On analysis of the data on the clinical ﬁndings and
course seen at or within a few years of the initial diagnosis
(Table 4), we found a statistically signiﬁcant trend for the
familial form of the disease to exhibit certain aggressive
features. A greater incidence of distant metastases (P =
0.03) was seen in the familial form of the disease, being6 Journal of Oncology
particularly prominent in the families with three or more
aﬀected members, the diagnosis being made in all of these
cases within 2 years of the initial diagnosis of thyroid cancer.
After the initial diagnosis and treatment, the familial cases
also had a signiﬁcantly greater requirement for reoperation
(P = 0.05) and, beyond 2 years of followup from the
initial therapy, had a signiﬁcantly greater need for further
treatment with radio-active iodine (P = 0.03). Of note, as
our mean followup times are short (ranging from 4.22 to
5.37 years) in all groups, these ﬁndings probably represent
persistenceofdiseaseratherthanrecurrence.Thesemeasures
of aggressiveness cannot be readily explained by a greater
incidence of tumours with histological features associated
with a more aggressive clinical course. There was only one
ﬁrst degree relative family member with the tall cell variant
of the disease, and this patient did not display any aggressive
features at surgery nor on clinical followup to date. Similarly,
the presence of foci of the solid-type growth pattern was seen
only in the nonfamilial cases. Nor can the trend for these
measures of aggressiveness in the familial form of the disease
be explained by an increased age at diagnosis since this factor
was not statistically diﬀerent between groups.
Triponez et al. [31] have reported that the survival rate of
aﬀected members of families with three or more members
was signiﬁcantly shorter than those in families with only
two aﬀected members; this would be consistent with more
aggressive disease being present in families with three or
more aﬀected members. In agreement with Charkes analysis
[26], features of aggressive disease in this study were most
frequently seen in the ﬁrst degree relative families with three
or more aﬀected members, and these appeared to cluster in
certain families; the distant metastases were present in only
5 of the 14 families, and the two deaths occurred in one
family. An analysis to explore for the possible presence of
heterogeneity in our families did not produce any statistical
evidence for such heterogeneity. However, the number of
events in our data may not have been suﬃcient to yield an
accurate appraisal of this possibility. With regard to the issue
of heterogeneity, Moses et al. [30] have recently published
a prospective study which found a similar heterogeneity
of numbers and types of somatic mutations in both the
sporadic and familial forms of well-diﬀerentiated thyroid
cancer cases; no evidence was seen for a clear genotype-
phenotypedistributionbasedonhereditarydisposition.This
question remains open for further genetic investigation.
The cases with features of aggressive disease were most
often present in the ﬁrst member diagnosed in the family.
Once the disease was recognized in the family, other aﬀected
members were usually diagnosed at an earlier stage of the
process and have fared better on followup to date. For
example,inoneofourfamilies,theinitialcasewasdiagnosed
late in the disease with multiple distant metastases as well as
inoperable local cervical disease. Two oﬀspring in this family
were screened for disease and both found to have micro-
papillary carcinomas which had penetrated the thyroid
capsule and spread to cervical nodes. Following surgery and
radio-iodine therapy, both are currently considered disease-
free (negative stimulated thyroglobulin levels). Similarly,
in an earlier report by Triponez et al. [31], it was found
that survival times were signiﬁcantly shorter for aﬀected
members treated before the familial nature of the disease was
recognized. Further, Moses et al. [30] found a statistically
signiﬁcant earlier age at diagnosis in familial patients and
attributes this to other family members being made aware
of the familial nature of the disease and, hence, presenting
at an earlier stage in the disease process. We did not see
a signiﬁcantly earlier age at diagnosis, but, by focusing
attention on the family history and encouraging family
members to undergo screening for the disease, we well may
have altered the outcomes in these patients for the better. A
potential problem biasing results in the opposite direction
would result from familial patients being more motivated to
present for followup procedures than patients with sporadic
PTC. If this occurred, less disease may have been discovered
in our sporadic PTC patients.
This study is retrospective in nature, which would be
expected to limit the completeness and accuracy of data
collection in patients treated in the earlier periods of this
study. Further, there have been signiﬁcant technological
advances over the period of data collection which has altered
our ability to detect the presence of persistent/recurrent
disease (e.g., advances in imaging, greater sensitivity and
speciﬁcity of thyroglobulin assays, and the determination
of stimulated thyroglobulin levels), rendering comparisons
over time somewhat more diﬃcult. Although the majority
of our cases were seen in the recent past, a minority of our
cases were ﬁrst diagnosed and treated at a time predating
current technical abilities. Our mean followup times are too
short to allow the comparison of clinical outcomes beyond
the period of a few years following the initial diagnosis. The
detection of persistent/recurrence of PTC may occur many
years after the initial diagnosis and therapy; microscopic
disease below the limits of detection at the time of initial
therapy may become apparent only with the passage of an
appreciable period of time. It is possible that diﬀerences in
longer-term clinical outcomes between sporadic and familial
disease may diﬀer from those seen with the shorter time of
followup in this study. However, the logistics of carrying out
a long-term prospective clinical research project to explore
this question are quite daunting. It is probable that ongoing
research will yield a better understanding of the disease with
the use of improved genetic diagnostic methods and imaging
techniques. A more precise approach to early diagnosis,
treatment and followup, may render such long-term clinical
studies unnecessary.
In summary, using a statistical approach (Chi square
by trend) that compared PTC in sporadic cases versus
ﬁrst degree relative families with two aﬀected members
versus ﬁrst degree relative families with three or more
aﬀected members, this study found evidence that the familial
form of the disease exhibits signiﬁcantly more aggressive
features (a) the presence of distant metastases found at or
shortly following the diagnosis of thyroid cancer and (b)
the requirement for reoperation or further treatment with
radio-active iodine following the initial treatment period. As
these features were predominantly seen in the ﬁrst degree
families with three or more aﬀected members, our results
support the ﬁndings and the suggestion of Charkes [26]Journal of Oncology 7
that genetic and clinical investigations should focus on
families with multiple aﬀected members. In agreement with
Triponez et al. [31], patients, diagnosed subsequent to the
recognition of the familial nature of the disease, tend to
have better outcomes. This underlines the importance of
early diagnosis and treatment for optimal outcomes. Until
reliable genetic testing becomes available, obtaining a good
family history is of great importance in the recognition
of the familial nature of well diﬀerentiated thyroid cancer
cases. Although the use of ultrasound as a routine screening
device is controversial, it is well recognized that signiﬁcantly
more nodules are seen on ultrasound examination than
are found on clinical examination, and that nodule size as
a predictor of the presence or absence of malignancy is
unreliable. In cases where the presence of FPTC is suspected,
the use of ultrasound for screening and the use of FNA
under ultrasound guidance on small lesions may result in
earlier diagnosis and better outcomes. Although this may be
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